tirzepatide efficacy and Safety of in Adults with Obesity or Overweight Published July 21, 2022 N Engl J Med 2022;387:205–216 🔹 Background Obesity and overweight remain major global health problems associated with Tirzepatide as Compared with Semaglutide

Abstract Diabetes mellitus, a condition that significantly elevates the incidence and mortality risks associated with cardiovascular diseases, exacerbates the disease burden in China

Gastrointestinal adverse events were most common in both groups and were mostly mild to moderate in severity

Simultaneously, leptin drops and adiponectin increases, both indicators that the body is processing energy and fat more efficiently

They sit near the top of the evidence hierarchy, just below meta-analyses (which combine multiple RCTs)

Pregnant or Nursing Semaglutide is not safe during pregnancy or breastfeeding

1000 mg high quality L-carnitine (Carnipure ) per ampoule